Stay updated on Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.

Latest updates to the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page
- Check2 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check23 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check52 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check59 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed descriptions of a phase II study involving OBP-301 and pembrolizumab for advanced gastric adenocarcinoma, and the addition of new collaborators and a revision number.SummaryDifference38%
- Check73 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.